Evidence map›Paper›PMID 41742228›Full record

ArticleJournal of translational medicine2026

Integrating trust into artificial intelligence for medicine: using diabetes as the exemplar disease.

Mandy M Shao, Agatha F Scheideman, David Kerr, Tien Y Wong, Juan Espinoza, Shahid N Shah, Mohammed E Al-Sofiani, Ashley N Beecy, Dieter Bruno, Elizabeth Healey and 5 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mandy M ShaoDiabetes Technology Society, 845 Malcolm Road, Suite 5, Burlingame, CA, 94010, USA.ORCID 0009-0004-9550-9965
Agatha F ScheidemanDiabetes Technology Society, 845 Malcolm Road, Suite 5, Burlingame, CA, 94010, USA. scheideman@diabetetechnology.org.ORCID 0009-0008-4211-4934
David KerrCenter for Health Systems Research, Sutter Health, Santa Barbara, CA, USA.ORCID 0000-0003-1335-1857
Tien Y WongTsinghua Medicine, Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital Eye Center, Tsinghua University, Beijing, China.ORCID 0000-0002-8448-1264
Juan EspinozaStanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.ORCID 0000-0003-0513-588X
Shahid N ShahNetspective Foundation, Inc., Silver Spring, MD, USA.ORCID 0000-0001-8481-6493
Mohammed E Al-SofianiDivision of Endocrinology, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0003-4420-9378
Ashley N BeecySutter Health, Emeryville, CA, USA.ORCID 0000-0002-1504-1169
Dieter BrunoMills-Peninsula Medical Center, Burlingame, CA, USA.
Elizabeth HealeyBoston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7307-8429
Nestoras MathioudakisSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-0210-655X
Bin ShengDepartment of Computer Science and Engineering, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-9874-7705
Michael P SnyderDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID 0000-0003-0784-7987
Yih Chung ThamDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-6752-797X
David C KlonoffDiabetes Research Institute, Mills-Peninsula Medical Center (Sutter Health), San Mateo, CA, USA.ORCID 0000-0001-6394-6862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial Intelligence (AI) has the potential to impact healthcare across multiple domains. In diabetes, a complex chronic disease affecting 600 million people globally, AI is already being used from primary care to tertiary specialist care to reduce patient and clinician burden. However, for medical AI to be widely implemented and applied specifically to diabetes, such stakeholders as patients, clinicians, healthcare administrators, regulators, and AI developers will need to establish trust in this technology. Building trust is a balancing act depending on individual priorities of stakeholders which may not necessarily align. Both probabilistic outputs and “top-choice only” outputs are used in medical AI. To achieve trust in AI for diabetes care, it will be necessary to move beyond expecting only single, deterministic outputs and to establish clear standards for medical AI provenance and performance. This article presents priorities for each of the various stakeholders if they are to develop trust in medical AI and their responsibilities for contributing to the establishment of trust in medical AI. For a medical AI system to be trustworthy, six key attributes must be incorporated including accuracy, reproducibility, privacy/security, transparency, human oversight, and fairness. We present practical methods to achieve each of these six attributes of trustworthy medical AI prioritizing diabetes that are important for all stakeholders.

Indexed as

Artificial IntelligenceDiabetes MellitusTrustHumansArtificial intelligenceHuman oversightMachine learningTransparencyTrust

Identifiers

PMID41742228
PMCPMC13041281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.